250 related articles for article (PubMed ID: 32267708)
21. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
Indulkar AS; Lou X; Zhang GGZ; Taylor LS
Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
[TBL] [Abstract][Full Text] [Related]
22. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
[TBL] [Abstract][Full Text] [Related]
23. Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion.
Van Eerdenbrugh B; Froyen L; Van Humbeeck J; Martens JA; Augustijns P; Van den Mooter G
Eur J Pharm Sci; 2008 Sep; 35(1-2):127-35. PubMed ID: 18644441
[TBL] [Abstract][Full Text] [Related]
24. Amorphous solid dispersion of ibuprofen: A comparative study on the effect of solution based techniques.
Ziaee A; O'Dea S; Howard-Hildige A; Padrela L; Potter C; Iqbal J; Albadarin AB; Walker G; O'Reilly EJ
Int J Pharm; 2019 Dec; 572():118816. PubMed ID: 31678527
[TBL] [Abstract][Full Text] [Related]
25. Investigation of Within-Tablet Dynamics for Extended Release of a Poorly Soluble Basic Drug from Hydrophilic Matrix Tablets Using ATR-FTIR Imaging.
Zahoor FD; Mader KT; Timmins P; Brown J; Sammon C
Mol Pharm; 2020 Apr; 17(4):1090-1099. PubMed ID: 32069060
[TBL] [Abstract][Full Text] [Related]
26. Enhance the dissolution rate and oral bioavailability of pranlukast by preparing nanosuspensions with high-pressure homogenizing method.
Wang L; Hao Y; Liu N; Ma M; Yin Z; Zhang X
Drug Dev Ind Pharm; 2012 Nov; 38(11):1381-9. PubMed ID: 22300415
[TBL] [Abstract][Full Text] [Related]
27. Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II/IV compounds.
Kesisoglou F; Mitra A
AAPS J; 2012 Dec; 14(4):677-87. PubMed ID: 22736294
[TBL] [Abstract][Full Text] [Related]
28. Millisecond Self-Assembly of Stable Nanodispersed Drug Formulations.
Pansare VJ; Rawal A; Goodwin A; Beyerinck R; Prud'homme RK; Friesen DT; Grass M; Muske-Dukes A; Vodak DT
Mol Pharm; 2018 Feb; 15(2):495-507. PubMed ID: 29244515
[TBL] [Abstract][Full Text] [Related]
29. The impact of the injection mold temperature upon polymer crystallization and resulting drug release from immediate and sustained release tablets.
Van Renterghem J; Dhondt H; Verstraete G; De Bruyne M; Vervaet C; De Beer T
Int J Pharm; 2018 Apr; 541(1-2):108-116. PubMed ID: 29409747
[TBL] [Abstract][Full Text] [Related]
30. Poly (D, L-lactide) nanosuspensions of risperidone for parenteral delivery: formulation and in-vitro evaluation.
Muthu MS; Singh S
Curr Drug Deliv; 2009 Jan; 6(1):62-8. PubMed ID: 19418957
[TBL] [Abstract][Full Text] [Related]
31. Formulation performance and processability window for manufacturing a dual-polymer amorphous solid dispersion via hot-melt extrusion and strand pelletization.
Hörmann TR; Jäger N; Funke A; Mürb RK; Khinast JG; Paudel A
Int J Pharm; 2018 Dec; 553(1-2):408-421. PubMed ID: 30326284
[TBL] [Abstract][Full Text] [Related]
32. Drug release characteristics from nanoclay hybrids and their dispersions in organic polymers.
Ha JU; Xanthos M
Int J Pharm; 2011 Jul; 414(1-2):321-31. PubMed ID: 21601624
[TBL] [Abstract][Full Text] [Related]
33. In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.
Andreas CJ; Chen YC; Markopoulos C; Reppas C; Dressman J
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):39-50. PubMed ID: 26391972
[TBL] [Abstract][Full Text] [Related]
34. Temperature-Induced Surface Effects on Drug Nanosuspensions.
Aleandri S; Schönenberger M; Niederquell A; Kuentz M
Pharm Res; 2018 Feb; 35(3):69. PubMed ID: 29468420
[TBL] [Abstract][Full Text] [Related]
35. Formulation and Evaluation of Naringenin Nanosuspensions for Bioavailability Enhancement.
Gera S; Talluri S; Rangaraj N; Sampathi S
AAPS PharmSciTech; 2017 Nov; 18(8):3151-3162. PubMed ID: 28534300
[TBL] [Abstract][Full Text] [Related]
36. Nanoamorphous drug products - Design and development.
Jog R; Burgess DJ
Int J Pharm; 2018 Dec; 553(1-2):238-260. PubMed ID: 30359685
[TBL] [Abstract][Full Text] [Related]
37. In vitro release testing method development for long-acting injectable suspensions.
Bao Q; Wang X; Zou Y; Wang Y; Burgess DJ
Int J Pharm; 2022 Jun; 622():121840. PubMed ID: 35595043
[TBL] [Abstract][Full Text] [Related]
38. Study of effect of variables on particle size of telmisartan nanosuspensions using box-Behnken design.
Rao MR; Bajaj A
Drug Res (Stuttg); 2014 Dec; 64(12):663-7. PubMed ID: 24549965
[TBL] [Abstract][Full Text] [Related]
39. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.
Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J
Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663
[TBL] [Abstract][Full Text] [Related]
40. Efavirenz Dissolution Enhancement IV-Antisolvent Nanocrystallization by Sonication, Physical Stability, and Dissolution.
Sartori GJ; Prado LD; Rocha HVA
AAPS PharmSciTech; 2017 Nov; 18(8):3011-3020. PubMed ID: 28493004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
